Boehringer Ingelheim GmbH - Strategy and SWOT Report
Boehringer Ingelheim GmbH - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.
Features:
Boehringer Ingelheim (BI) is a global group of companies owned by the founding Boehringer family through the parent company, C. H. Boehringer Sohn AG & Co. KG. The group is engaged in the research, development, manufacture and marketing of branded and generic prescription drugs, consumer health care products, industrial chemicals, and animal health products. The group operates in Europe, the Americas, Asia, Australasia and Africa. BI is headquartered in Ingelheim, Germany and employed 41,354 people as of December 2009. The company recorded revenues* of E13,661 million ($19,052 million**) during the financial year (FY) ended December 2009, an increase of 10.6% over FY2008. The operating profit of the company was E2,239 million ($3,122.6 million**) during FY2009, an increase of 13.1% over FY2008. The net profit was E1,759 million ($2,453.2 million**) in FY2009, an increase of 23.5% over FY2008. * Revenues = Net sales + changes in inventories + other internal work performed and capitalized + other operating income. ** Calculated using the constant conversion rate of E1 = $1.39463 for the year ended December 31, 2009.
Reasons to Purchase:
Boehringer Ingelheim (BI) is a global group of companies owned by the founding Boehringer family through the parent company, C. H. Boehringer Sohn AG & Co. KG. The group is engaged in the research, development, manufacture and marketing of branded and generic prescription drugs, consumer health care products, industrial chemicals, and animal health products. The group operates in Europe, the Americas, Asia, Australasia and Africa. BI is headquartered in Ingelheim, Germany and employed 41,354 people as of December 2009. The company recorded revenues* of E13,661 million ($19,052 million**) during the financial year (FY) ended December 2009, an increase of 10.6% over FY2008. The operating profit of the company was E2,239 million ($3,122.6 million**) during FY2009, an increase of 13.1% over FY2008. The net profit was E1,759 million ($2,453.2 million**) in FY2009, an increase of 23.5% over FY2008. * Revenues = Net sales + changes in inventories + other internal work performed and capitalized + other operating income. ** Calculated using the constant conversion rate of E1 = $1.39463 for the year ended December 31, 2009.
Features:
- Detailed information on Boehringer Ingelheim GmbH required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Boehringer Ingelheim GmbH in the form of a SWOT analysis
- An in-depth view of the business model of Boehringer Ingelheim GmbH including a breakdown and examination of key business segments
- Intelligence on Boehringer Ingelheim GmbH’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Boehringer Ingelheim GmbH, such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends
Boehringer Ingelheim (BI) is a global group of companies owned by the founding Boehringer family through the parent company, C. H. Boehringer Sohn AG & Co. KG. The group is engaged in the research, development, manufacture and marketing of branded and generic prescription drugs, consumer health care products, industrial chemicals, and animal health products. The group operates in Europe, the Americas, Asia, Australasia and Africa. BI is headquartered in Ingelheim, Germany and employed 41,354 people as of December 2009. The company recorded revenues* of E13,661 million ($19,052 million**) during the financial year (FY) ended December 2009, an increase of 10.6% over FY2008. The operating profit of the company was E2,239 million ($3,122.6 million**) during FY2009, an increase of 13.1% over FY2008. The net profit was E1,759 million ($2,453.2 million**) in FY2009, an increase of 23.5% over FY2008. * Revenues = Net sales + changes in inventories + other internal work performed and capitalized + other operating income. ** Calculated using the constant conversion rate of E1 = $1.39463 for the year ended December 31, 2009.
Reasons to Purchase:
- Gain understanding of the Boehringer Ingelheim GmbH and the factors that influence its strategies
- Track strategic initiatives of the company and latest corporate news and actions
- Assess Boehringer Ingelheim GmbH as a prospective partners, vendor or supplier
- Support sales activities by understanding your customers' businesses better
- Stay up to date on Boehringer Ingelheim GmbH’s business structure, strategy and prospects
Boehringer Ingelheim (BI) is a global group of companies owned by the founding Boehringer family through the parent company, C. H. Boehringer Sohn AG & Co. KG. The group is engaged in the research, development, manufacture and marketing of branded and generic prescription drugs, consumer health care products, industrial chemicals, and animal health products. The group operates in Europe, the Americas, Asia, Australasia and Africa. BI is headquartered in Ingelheim, Germany and employed 41,354 people as of December 2009. The company recorded revenues* of E13,661 million ($19,052 million**) during the financial year (FY) ended December 2009, an increase of 10.6% over FY2008. The operating profit of the company was E2,239 million ($3,122.6 million**) during FY2009, an increase of 13.1% over FY2008. The net profit was E1,759 million ($2,453.2 million**) in FY2009, an increase of 23.5% over FY2008. * Revenues = Net sales + changes in inventories + other internal work performed and capitalized + other operating income. ** Calculated using the constant conversion rate of E1 = $1.39463 for the year ended December 31, 2009.
Contents
Company SnapshotBoehringer Ingelheim GmbH: Company Overview
Boehringer Ingelheim GmbH: Overview and Key Facts
Boehringer Ingelheim GmbH: Overview
Boehringer Ingelheim GmbH: Key Facts
Boehringer Ingelheim GmbH: Key Employees
Boehringer Ingelheim GmbH: Major Products and Services
Boehringer Ingelheim GmbH: Company History
Boehringer Ingelheim GmbH: Management Statement
Boehringer Ingelheim GmbH: Locations and Subsidiaries
Boehringer Ingelheim GmbH: Key Competitors
Boehringer Ingelheim GmbH: Company Analysis
Boehringer Ingelheim GmbH: Business Description
Boehringer Ingelheim GmbH: SWOT Analysis
Boehringer Ingelheim GmbH: SWOT Overview
Boehringer Ingelheim GmbH: Strengths
Boehringer Ingelheim GmbH: Weaknesses
Boehringer Ingelheim GmbH: Opportunities
Boehringer Ingelheim GmbH: Threats
Boehringer Ingelheim GmbH: Corporate Financial Deals Activity
Boehringer Ingelheim GmbH: Financial Deals Overview
Boehringer Ingelheim GmbH: Targets and Partners
Boehringer Ingelheim GmbH: Top Deals 2007 -YTD*2011
Boehringer Ingelheim GmbH: Mergers and Acquisitions
Boehringer Ingelheim GmbH: Corporate Venturing
Boehringer Ingelheim GmbH: Partnership
Boehringer Ingelheim GmbH: Recent Developments
Boehringer Ingelheim GmbH: News and Events Summary
Boehringer Ingelheim GmbH: Business Expansion
Boehringer Ingelheim GmbH: Contracts
Boehringer Ingelheim GmbH: Regulatory and Legal Events
Boehringer Ingelheim GmbH: Research & Development
Boehringer Ingelheim GmbH: Strategy and Operations
Appendix
Contact Us
Methodology
Definitions
About Datamonitor
LIST OF TABLES
Table 1: Boehringer Ingelheim GmbH: Key Facts
Table 2: Boehringer Ingelheim GmbH: Key Employees
Table 4: Boehringer Ingelheim GmbH: Key Competitors
Table 5: Boehringer Ingelheim GmbH: Deal Activity by Deal Type - Volume (TTM)
Table 6: Boehringer Ingelheim GmbH: M&A Activity by Geography (TTM)
Table 7: Boehringer Ingelheim GmbH: Deal Activity by Deal Type - Volume (2007 - YTD*2011)
Table 8: Boehringer Ingelheim GmbH: M&A Average Deal Size - Value (US$m)
Table 9: Boehringer Ingelheim GmbH: Targets and Partners
Table 10: Boehringer Ingelheim GmbH: Top Deals 2007 -YTD*2011
Table 11: Boehringer Ingelheim GmbH: M&A Volume and Value Trend (2007 - YTD*2011)
Table 12: Boehringer Ingelheim GmbH: M&A Activity by Geography (2007 - YTD*2011)
Table 13: Boehringer Ingelheim GmbH: Corporate Venturing Volume and Value Trend (2007 - YTD*2011)
Table 14: Boehringer Ingelheim GmbH: Corporate Venturing by Geography (2007 - YTD*2011)
Table 15: Boehringer Ingelheim GmbH: Partnership Volume and Value Trend (2007 - YTD*2011)
Table 16: Boehringer Ingelheim GmbH: Partnership Trend by Deal Type (2007 - YTD*2011)
Table 17: Boehringer Ingelheim GmbH: News and Events Summary
Table 18: Boehringer Ingelheim GmbH: Business Expansion
Table 19: Boehringer Ingelheim GmbH: Contracts
Table 20: Boehringer Ingelheim GmbH: Regulatory and Legal Events
Table 21: Boehringer Ingelheim GmbH: Research & Development
Table 22: Boehringer Ingelheim GmbH: Strategy and Operations
LIST OF FIGURES
Figure 1: Boehringer Ingelheim GmbH: Deal Activity by Deal Type - Volume (TTM)
Figure 2: Boehringer Ingelheim GmbH: M&A Activity by Geography (TTM)
Figure 3: Boehringer Ingelheim GmbH: Deal Activity by Deal Type - Volume (2007 - YTD*2011)
Figure 4: Boehringer Ingelheim GmbH: M&A Average Deal Size - Value (US$m)
Figure 5: Boehringer Ingelheim GmbH: M&A Volume and Value Trend (2007 - YTD*2011)
Figure 6: Boehringer Ingelheim GmbH: M&A Activity by Geography (2007 - YTD*2011)
Figure 7: Boehringer Ingelheim GmbH: Corporate Venturing Volume and Value Trend (2007 - YTD*2011)
Figure 8: Boehringer Ingelheim GmbH: Corporate Venturing by Geography (2007 - YTD*2011)
Figure 9: Boehringer Ingelheim GmbH: Partnership Volume and Value Trend (2007 - YTD*2011)
Figure 10: Boehringer Ingelheim GmbH: Partnership Trend by Deal Type (2007 - YTD*2011) Skip to top